I was no stranger to the tensions at Bayer when I joined as CEO last June. Multiple complex challenges face our business.

despite resistance from some Bayer shareholders who were concerned it was buying a struggling business and could be diverted from its higher-margin pharma focus. The CEO survived a no-confidence ...